Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global AL amyloidosis therapeutics market was valued at US$ 2.13 billion in 2022 and is expected to register a revenue CAGR of 7.25% to reach US$ 3.73 billion by 2031.

AL Amyloidosis Therapeutics Market Fundamentals

Amyloid light chain (AL) amyloidosis is a fatal plasma cell condition defined by the deposition of fibrils of misfolded IgG-free light chains (FLC) in target organs. Cardiac involvement is prevalent in AL amyloidosis and is the most detrimental prognostic factor. To halt the progress of amyloid deposition and preserve organ function, a high index of clinical suspicion, quick tissue diagnosis, and the initiation of combinatorial, highly efficient cytoreductive therapy are required. 

The prominent AL amyloidosis market trends include many advancements in treating and diagnosing AL amyloidosis. There have been significant breakthroughs in the diagnosis, prognosis, and management of AL amyloidosis in recent years. The recent introduction of innovative antiplasmin cell medicines into clinical practice has fundamentally altered the therapy model, resulting in better responses, improved long-term survival outcomes, and decreased toxicity. 

Market players continuously employ various techniques to enhance their revenue in the AL amyloidosis therapeutics market. Major market players increasingly spend on R&D to discover novel remedies that meet unmet medical needs. This can assist companies in gaining a larger market revenue share and increasing revenue. Furthermore, market players might broaden their geographical reach by entering new markets or collaborating with local distributors. This can assist them in reaching out to new patient populations and increasing their sales. 

[123]

AL Amyloidosis Therapeutics Market Dynamics 

The increasing prevalence of AL amyloidosis is the major factor driving the global amyloidosis therapeutics market revenue. Amyloidosis affects an estimated 9 to 14 persons per million in the United States and 5 to 12 people per million worldwide. Males are more likely to develop AL amyloidosis than females. It typically affects adult people aged 60 to 64. This rate is expected to increase during the forecast period due to the increasing geriatric population and increasing awareness of advanced diagnostics and treatment. 

Advancements in diagnostics and treatment for AL amyloidosis are expected to boost the revenue growth of the global AL amyloidosis therapeutics market. With the latest advancements in diagnostics and treatment, patients can receive more accurate diagnoses and personalized care plans, leading to improved outcomes and quality of life. Recently, serum-free light chain tests have gained popularity in diagnosing AL amyloidosis. The serum FLC assay determines the blood’s free light chains (kappa and lambda) concentrations. In some situations, the test can detect monoclonal gammopathy, a precursor to AL amyloidosis. Similarly, immunochemistry and mass spectrometry are other techniques that allow for the identification of the specific type of amyloid protein deposited, which is critical for determining the appropriate treatment.

There has been an increase in research and development in AL amyloidosis therapies. Pharmaceutical companies and research organizations are working hard to provide new medications and treatment methods to meet the unmet medical needs of AL amyloidosis patients. Combination therapy, including numerous medicines or treatment modalities, is gaining popularity in treating AL amyloidosis. Combination medicines have demonstrated the ability to improve therapeutic effectiveness and overcome medication resistance. Clinical studies are underway to assess the safety and effectiveness of various combination treatments for AL amyloidosis. For instance, in April 2020, the British Journal of Hematology stated that using proteasome inhibitors and immunotherapy agents has produced favorable outcomes in AL amyloidosis patients. 

Collaborations and partnerships allow businesses to leverage strengths and resources to achieve common goals. This trend is driven by the need to develop innovative and effective treatments for AL amyloidosis. For instance, AstraZeneca acquired Caelum Biosciences in 2021. This merge is expected to drive market revenue during the future period. Moreover, a robust pipeline of innovative targeted treatments for AL amyloidosis will likely create lucrative market revenue growth possibilities. For instance, in May 2020, the FDA approved an investigational new medication application for STI-6129 by Sorrento Therapeutics, Inc., a CD38-targeting monoclonal antibody combination. Sorrento Therapeutics is developing a range of technical platforms, including a CD38-specific antibody from its fully human G-MABTM antibody library, its pharmacological payload Duostatin 5, and its site-specific C-LOCK coupling technology. STI-6129 makes use of all these platforms.

However, the high treatment costs and lack of awareness may limit the overall revenue growth of the global AL amyloidosis therapeutics market.  Furthermore, many pharmaceutical companies limited operating revenue opportunities for research and development of targeted medicines pose a challenge to the market revenue growth.

AL Amyloidosis Therapeutics Market Ecosystem

The global AL amyloidosis therapeutics market is analyzed from three perspectives: treatment, drugs, distribution channel, and region. 

AL Amyloidosis Therapeutics Market by Treatment

[456]

The global AL amyloidosis therapeutics market is segmented based on treatment: surgery, stem cell transplant, and medications. 

The medications segment dominated the global AL amyloidosis therapeutics market, with the majority of the market revenue share in 2022. The segment is sub-segmented into transthyretin transport inhibitors, immunomodulatory drugs, monoclonal antibodies, proteasome inhibitors, chemotherapy drugs, and others. Transthyretin transport inhibitors are expected to dominate the market due to their high efficacy in treating AL amyloidosis. Transthyretin transport inhibitors have shown promising results in clinical trials as a potential treatment for this condition. Transthyretin transport inhibitors are considered a viable treatment option for Al amyloidosis. These inhibitors function by stabilizing transthyretin and preventing it from dissociating into monomers, a critical stage in the development of amyloid fibrils.

However, the monoclonal antibodies segment is expected to grow significantly due to the increasing number of clinical trials and approvals for these drugs. Monoclonal antibodies have shown encouraging outcomes. These antibodies seek out and destroy aberrant plasma cells that create amyloid proteins, which cause organ damage. Monoclonal antibodies have been developed as a safe and effective therapy for patients with AL amyloidosis. They have also improved survival rates and quality of life in advanced disease patients.

The stem cell transplantation segment is expected to register a high revenue share in the forecast years. Autologous stem cell transplant is an extremely successful stem cell treatment for AL amyloidosis. The enhanced survival and much lower treatment-related mortality in eligible patients suggest that this will remain an essential first-line choice even in the era of innovative therapeutic techniques. Moreover, the treatment involves the collection of the patient’s stem cells, which are then treated and transplanted back into the patient. It effectively improves survival rates and reduces the risk of treatment-related complications. 

AL Amyloidosis Therapeutics Market by Region

Based on the region, the global AL amyloidosis therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, & the Middle East & Africa.

North America accounted for the largest AL amyloidosis therapeutics market revenue share in 2022. The increasing prevalence of AL amyloidosis in North America and the growing demand for effective treatment alternatives are the primary factors driving the region’s AL amyloidosis therapeutics market. Furthermore, increased investments in research & development efforts for innovative medicines will likely drive market expansion. Additionally, the rising geriatric population and the subsequent increase in the incidence of AL amyloidosis are expected to fuel market revenue growth in North America further. However, stringent regulatory requirements and high costs associated with drug development may hinder market revenue growth.

The AL amyloidosis therapeutics market in Europe is characterized by numerous significant market players actively involved in the R&D and commercialization of innovative treatments for AL amyloidosis treatment. The rising prevalence of this condition and the growing demand for better treatment alternatives will likely fuel regional market revenue expansion during the forecast period. Moreover, the increasing healthcare expenditure and favorable government initiatives to improve the healthcare infrastructure in Europe are expected to provide lucrative revenue growth opportunities for market players operating in the AL amyloidosis therapeutics market. 

The Asia Pacific AL amyloidosis therapeutics market revenue is expected to increase significantly during the forecast period due to rising demand for healthcare services, rising healthcare expenditure, and the integration of new technology in diagnosing the AL amyloidosis therapeutics market. Furthermore, the expanding number of hospitals and healthcare facilities in countries such as China and India will likely boost market revenue expansion in the region. Moreover, increased R&D initiatives, such as top pharmaceutical companies collaborating with research and academic institutes, influence the AL amyloidosis therapeutics market. Additionally, the growing awareness about the disease and its diagnosis among patients and healthcare professionals will propel market revenue expansion.

Competitive Landscape of the Global AL Amyloidosis Therapeutics Market

The competitive landscape of the AL amyloidosis therapeutics market is constantly evolving with the emergence of new players and advancements in technology. The major players in the market are focusing on strategic collaborations, partnerships, and acquisitions to expand their product portfolio and support their market position. Additionally, the increasing prevalence of AL amyloidosis and the growing demand for effective treatment options are expected to drive market revenue in the coming years. Moreover, adopting novel therapies is also expected to boost market revenue growth. 

The prominent players operating in the global AL amyloidosis therapeutics market are:

• Janssen Pharmaceutical, Inc.   
• Alexion Pharmaceuticals, Inc.
• Oncopeptides AB 
• Bristol-Myers Squibb Company 
• Celgene Corporation
• Eidos Therapeutics, Inc.
•  Corino Therapeutics, Inc.
•  Spectrum Pharmaceuticals, Inc.
• Pfizer Inc.

Strategic Developments in the Global AL Amyloidosis Therapeutics Market

In January 2021, Janssen Biotech announced that the Food and Drug Administration (FDA) had approved daratumumab with hyaluronidase in combination with bortezomib, dexamethasone, and cyclophosphamide for newly diagnosed light chain (AL) amyloidosis. The Phase III ANDROMEDA research assesses daratumumab and hyaluronidase for identifying newly identified light chain (AL) amyloidosis, a rare blood cell condition linked to the deterioration of important organs, most notably the kidneys, heart, and liver, recently revealed updated good results.

Frequently Asked Questions About This Report